In the last trading session, 1.58 million shares of the Altimmune Inc (NASDAQ:ALT) were traded, and its beta was 0.79. Most recently the company’s share price was $5.89, and it changed around -$0.16 or -2.64% from the last close, which brings the market valuation of the company to $453.61M. ALT currently trades at a discount to its 52-week high of $11.16, offering almost -89.47% off that amount. The share price’s 52-week low was $5.14, which indicates that the current value has risen by an impressive 12.73% since then. We note from Altimmune Inc’s average daily trading volume that its 10-day average is 3.6 million shares, with the 3-month average coming to 2.55 million.
Altimmune Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.36. If we narrow it down even further, the data shows that 0 out of 10 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 2 recommended ALT as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Altimmune Inc is expected to report earnings per share of -0.37 for the current quarter.
Altimmune Inc (NASDAQ:ALT) trade information
Instantly ALT has showed a red trend with a performance of -2.64% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 6.16 on recent trading dayincreased the stock’s daily price by 4.38%. The company’s shares are currently down -18.31% year-to-date, but still up 4.99% over the last five days. On the other hand, Altimmune Inc (NASDAQ:ALT) is -3.60% down in the 30-day period. We can see from the shorts that 22.45 million shares have been sold at a short interest cover period of 7.0 day(s).
The consensus price target as assigned by Wall Street analysts is $25, which translates to bulls needing to increase their stock price by 76.44% from its current value. Analyst projections state that ALT is forecast to be at a low of $12 and a high of $35.
Altimmune Inc (ALT) estimates and forecasts
The year-over-year growth rate is expected to be 99,910.00%, up from the previous year.
Consensus estimates provided by 10 financial analysts predict the company will bring in an average of 500 in revenue for the current quarter. 10 analysts expect Altimmune Inc to make 500 in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 5k and 5k respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -90.00%. Forecasts for the next quarter put sales growth at -90.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 3.48%. Altimmune Inc earnings are expected to increase by -10.70% in 2025, but the outlook is negative -2.61% per year for the next five years.
ALT Dividends
Altimmune Inc’s next quarterly earnings report is expected to be released on 2025-Feb-26.
Altimmune Inc (NASDAQ:ALT)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.84% of Altimmune Inc shares, and 53.69% of them are in the hands of institutional investors. The stock currently has a share float of 54.14%. Altimmune Inc stock is held by 246.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 7.5025% of the shares, which is about 5.32 million shares worth $35.39 million.
VANGUARD GROUP INC, with 6.9301% or 4.91 million shares worth $32.63 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 2.24 shares worth $13.18 million, making up 2.90% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 1.92 shares worth around $11.32 million, which represents about 2.49% of the total shares outstanding.
